Rochester General Hospital Begins Stem Cell Study For Crohn's Disease
May 26, 2011
Rochester General Hospital is one of 16 sites participating in a study of placenta-derived stem cells in the treatment of Crohn’s disease in adults.
48 patients from all sites in the US and Canada will be enrolled in the Phase 2 study which, for the first time, tests the drug on the populations for which it is intended.
The trial focuses on safety, dosing and efficacy. During the study, neither the patient nor the physician knows whether the patient is receiving active medication.
This study will test the safety and efficacy of intravenous infusion of human placenta- derived cells for the treatment of adults with moderate-to-severe Crohn’s disease.
Patients will be receive two infusions one week apart and then will have another chance to receive another two infusions, depending on their reaction to the first set of treatments. The patients will be followed for approximately two years.
For information about the study, call Rochester General Hospital at (585) 922-3639.
More information about the Rochester General Research Institute
More information about Crohn's Disease